Abstract
Objectives: to review the available evidence regarding the treatment of neuropathic pain.
Methodology: given the work undertaken by other HTA agencies, the scope was limited to systematic reviews or clinical practice guidelines published since 2007, using both free and controlled language for the search. The sources have been TripDatabese, PubMed, National Guideline Clearinghouse
Results: three GPC and 19 documents met the inclusion criteria. Different agencies evaluation value as treatments of choice for neuropathic pain tricyclic antidepressants (amitriptyline) or
anticonvulsants (gabapentin or pregabalina). Depending on the data available in each case, different priority. Apordada information for all relevant documents is submitted incomplete, so it is difficult to make generalizations.
Conclusions: the amitriptyline has been shown effective and efficient in the treatment of neuropathic pain. Pregabalina and gabapentin also, but with a better security profile and greater cost. No items allow saying that it allows more effective as pregabalina or gabapentin, so are not given their choice of higher cost.
Keywords
neuropathic pain; Pharmacological Treatment
Bibliographic citation
Solà-Morales O. Revisió de l’eficàcia dels diferents tractaments farmacològics del dolor neuropàtic. 2a ed. Barcelona: Agència d’Informació, Avaluació i Qualitat en Salut; 2011.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3087This item appears in following collections
The following license files are associated with this item: